34th week of 2012 patent applcation highlights part 34 |
Patent application number | Title | Published |
20120213783 | ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 CHIMERIC ANTIGEN RECEPTORS AND USE OF SAME FOR THE TREATMENT OF CANCER - The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of a KDR-1121 or DC101 antibody, an extracellular hinge domain, a T cell receptor transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed. | 2012-08-23 |
20120213785 | ANTI-NOTCH3 AGONIST ANTIBODIES AND THEIR USE IN THE TREATMENT OF NOTCH3-RELATED DISEASES - The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders. | 2012-08-23 |
20120213786 | Notch1 Binding Agents and Methods of Use Thereof - The present invention relates to Notch1 binding agents and methods of using the agents for treating diseases, such as hematologic cancers. The present invention provides antibodies that specifically bind to a non-ligand binding membrane proximal region of the extracellular domain of human Notch1. The present invention further provides methods of using agents that inhibit Notch1 activity for treating cancer. Also described are methods of treating hematologic cancers comprising administering a therapeutically effective amount of a binding agent or antibody of the present invention to a subject having a hematologic cancer such as T-cell lymphoblastic leukemia. | 2012-08-23 |
20120213787 | STABLE ANTI-TNFR1 POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS - The invention relates to storage-stable anti-TNFR1 antibody single variable domains (dAbs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or COPD, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient. | 2012-08-23 |
20120213788 | USE OF INHIBITORS OF LEUKOTRIENE B4 RECEPTOR BLT2 FOR TREATING HUMAN CANCERS - The present invention relates to the use of inhibitors of leukotriene B4 receptor BLT2 for treating human cancers. More particularly, the present invention relates to a pharmaceutical composition for treating human cancers comprising BLT2 inhibitors and a method for treating human cancers using BLT2 inhibitors. | 2012-08-23 |
20120213789 | New Molecular Target for Treatment of Cancer - The present invention concerns preventative, therapeutic, and diagnostic methods and compositions involving UC markers, such as UC 28, for cancer. It includes methods and compositions for targeting cancer cells using a differentiation agent in combination with a therapeutic agent targeted to cells that differentially express a UC marker after exposure to the differentiation agent. The invention also includes methods of inducing immune responses against UC markers, as well as antibodies that recognize UC markers, which may be employed for therapeutic and diagnostic methods. | 2012-08-23 |
20120213790 | METHODS OF TREATMENT USING IL-16 ANTAGONIST PEPTIDES - The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases. | 2012-08-23 |
20120213791 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS - The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof, and combinations thereof with other anti-cancer agents, for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3. | 2012-08-23 |
20120213792 | HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING - Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention. | 2012-08-23 |
20120213793 | CANCER TREATMENT - The present invention relates to methods of treating cancer, such as melanoma, by administering a CTLA4 antagonist to a subject with a serum C-Reactive Protein (CRP) concentration that is less than or equal to some amount. The invention further relates to methods of treating cancer by determining the level of serum CRP concentration in a subject, and then administering a CTLA4 antagonist if the CRP concentration is less than or equal to a certain amount. The invention further relates to, among other things, the use of serum CRP concentration as a predictive factor for a subjects response to a cancer treatment. | 2012-08-23 |
20120213794 | AX213 AND AX132 PSCK9 ANTAGONISTS AND VARIANTS - Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure. | 2012-08-23 |
20120213795 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases are therapeutically useful. | 2012-08-23 |
20120213796 | POLYCLONAL ANTIBODY COMPOSITIONS - The present invention provides purified immunoglobulin compositions derived from the colostrum of a bovine immunized with a target antigen. The immunoglobulin composition comprises polyclonal antibodies specific for the target antigen and is depleted of non-immunoglobulin factors. The invention includes methods of manufacturing the compositions of the invention. The invention further includes pharmaceutical formulations comprising a purified immunoglobulin composition of the invention and an optional pharmaceutically acceptable excipient. | 2012-08-23 |
20120213797 | ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) - Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described. | 2012-08-23 |
20120213798 | METHODS AND USES FOR TREATING HEPATIC ISCHEMIA AND REPERFUSION INJURY - The present disclosure provides a method of treating or preventing hepatic ischemia and reperfusion injury in an animal comprising administering an effective amount of an FGL | 2012-08-23 |
20120213799 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS - The present invention features compositions and methods related to humanized antibodies and FKN-binding fragments thereof that bind fractalkine. | 2012-08-23 |
20120213800 | Methods for treating and diagnosing disease - The present invention provides methods for the diagnosis and/or treatment of chronic kidney disease, immune complex-mediated GN, rheumatoid arthritis, and pulmonary fibrosis, and methods for identifying compounds for such therapeutic use. | 2012-08-23 |
20120213801 | Phosphorylated Twist1 and cancer - The present application relates to methods for treating cancer in a subject by modulating the phosphorylation of the Serine 42 of Twist1 by administering to said subject a therapeutically effective amount of a modulator of said phosphorylation of the Serine 42 of Twist1. Antibodies, uses methods and biomarkers based on the phosphorylation of the Serine 42 of Twist1 are also provided. | 2012-08-23 |
20120213802 | PAR-1 Antagonists for Use in the Treatment or Prevention of Influenza Virus Type A Infections - The present invention provides methods and compositions (such as pharmaceutical compositions) comprising PAR1 antagonists for treating or preventing influenza virus type A infections, in particular H1N1 infection. PAR1 antagonists may be combined with a PAR2 agonist. | 2012-08-23 |
20120213803 | METHODS FOR DIAGNOSING AND TREATING ENCEPHALITIS OR EPILEPSY - This invention provides methods of diagnosing or determining a cause of an autoimmune encephalitis or an epilepsy in a subject and of diagnosing a tumor in a subject, comprising the step of testing a biological sample of the subject for an anti-body to a GABA | 2012-08-23 |
20120213804 | CALICHEAMICIN DERIVATIVE-CARRIER CONJUGATES - Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. | 2012-08-23 |
20120213805 | Amatoxin-Armed Tartget-Binding Moieties for the Treatment of Cancer - The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of target-binding moieties and toxins that are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moieties (e.g. antibodies) are directed against tumour-associated antigens, such as epithelial cell adhesion molecule (EpCAM). In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer, in particular adenocarcinoma, such as pancreatic cancer, cholangiocarcinoma, breast cancer, and colorectal cancer. | 2012-08-23 |
20120213806 | NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula: | 2012-08-23 |
20120213807 | NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula: | 2012-08-23 |
20120213808 | CARBONIC ANHYDRASE I SERVING AS NOVEL ANTIGEN TO BE USED FOR TREATMENT OF AUTOIMMUNE DISEASES - The purpose of the present invention is to provide a method for treating autoimmune diseases. Disclosed is a method or the like for the treatment of autoimmune diseases, which utilizes an antigen-specific tolerogenic antigen presenting cell. Specifically disclosed are: a method for producing an antigen-specific tolerogenic antigen presenting cell, which is characterized by using carbonic anhydrase I; an immunogenic antigen presenting cell which is specific to carbonic anhydrase I; and a method or the like for the treatment of autoimmune diseases (especially inflammatory bowel diseases), which is characterized by using a tolerogenic antigen presenting cell which is specific to carbonic anhydrase I. | 2012-08-23 |
20120213809 | VAULT COMPLEXES FOR CYTOKINE DELIVERY - The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer. | 2012-08-23 |
20120213810 | NOVEL EUROPEAN PRRSV STRAIN - The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines. | 2012-08-23 |
20120213811 | CHIMERIC HIV FUSION PROTEINS AS VACCINES - A method for treating HIV infection is disclosed. The method comprises administering to a patient in need thereof a therapeutically effective amount of a fusion protein comprising: a) a | 2012-08-23 |
20120213812 | Immunostimulatory Oligonucleotides - Compositions that include immunostimulatory nucleic acids are disclosed, along with the use of such compositions to induce immune responses. | 2012-08-23 |
20120213813 | ALPHAVIRUS REPLICON PARTICLES AS IMMUNOLOGICAL ADJUVANTS - The immune response to an antigen of interest, either in purified form or expressed via an alphavirus replicon particle, can be enhanced by the simultaneous administration of an alphavirus replicon particle which expresses interleukin-12. This allows for the use of significantly smaller quantities of the antigen and this immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen. | 2012-08-23 |
20120213814 | MODIFICATION OF RECOMBINANT ADENOVIRUS WITH IMMUNOGENIC PLASMODIUM CIRCUMSPOROZOITE PROTEIN EPITOPES - The present disclosure relates to adenovirus protein modifications to augment immune response to a transgene of a recombinant adenovirus and to circumvent pre-existing anti-adenovirus immunity. Some embodiments are directed to a recombinant adenovirus derived from a recombinant adenovirus plasmid vector, wherein the recombinant adenovirus plasmid vector comprises a nucleotide sequence encoding a | 2012-08-23 |
20120213815 | VACCINES AND IMMUNOTHERAPEUTICS USING CODON-OPTIMIZED IL-15 AND METHODS FOR USING THE SAME - Nucleic acid molecules that encode IL-15 or fragments thereof, which express protein at a higher level than nucleic acid molecules with native coding sequences for IL-15 are disclosed. Nucleic acid molecules with additional modifications such as the absence of coding sequences for IL-15 signal sequences and/or the absence of IL-15 untranslated sequences and/or inclusion of non-IL-15 signal sequences are also disclosed. Vectors, including plasmids and viral vectors, comprising such nucleic acid molecules; and to host cells comprising such nucleic acid molecules are disclosed as well as methods of using such nucleic acid molecules alone or in combination with nucleic acid sequences encoding immunogens which are part of the nucleic acid molecules and/or part of a different nucleic acid molecule. Recombinant vaccines and live attenuated pathogens encoding fusion proteins, and methods of using the same, are disclosed. | 2012-08-23 |
20120213816 | MYCOPLASMA HYOPNEUMONIAE BACTERIN VACCINE - The invention provides an improved | 2012-08-23 |
20120213817 | CHIMERIC RSV-F POLYPEPTIDE AND LENTIVIRUS OR ALPHA-RETROVIRUS GAG-BASED VLPS - The present invention relates to chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus GAG-based virus-like particles (VLPs). The present invention also includes methods of making and using such chimeric VLPs. In certain embodiments, the GAG polypeptide of the chimeric VLPs comprises an HIV or ALV GAG polypeptide. | 2012-08-23 |
20120213818 | COMBINATION THERAPY FOR IMMUNOSTIMULATION - The present invention relates to a method for immunostimulation in a mammal which comprises | 2012-08-23 |
20120213819 | HEMAGGLUTININ POLYPEPTIDES, AND REAGENTS AND METHODS RELATING THERETO - The present invention provides a system for analyzing interactions between glycans and interaction partners that bind to them. The present invention also provides HA polypeptides that bind to umbrella-topology glycans, and reagents and methods relating thereto. | 2012-08-23 |
20120213820 | Pharmaceutical composition for the treatment and prevention of a rhinovirus infection - The present invention relates to a pharmaceutical composition comprising at least one peptide consisting of a minimum of 8 and a maximum of 50 amino acid residues comprising amino acid residues 1 to 8 of a rhinovirus capsid protein selected from the group consisting of VP1, VP2, VP3 and VP4. | 2012-08-23 |
20120213821 | NOVEL METHOD FOR ISOLATING ENDOTOXINS - The invention concerns a novel method for extracting endotoxins from bacteria, and the use of said method for preparing compositions comprising endotoxins or derivatives thereof designed for human or animal use (scientific, medical usage). | 2012-08-23 |
20120213822 | CHEMO-IMMUNOTHERAPY METHOD - A method of treating or preventing disease, said method comprising administering to a subject, simultaneously, sequentially or separately, an antigen and a chemotherapeutic agent or agents comprising the steps of: administering the chemotherapeutic agent or agents, and administering an antigen up to 6 weeks after the chemotherapeutic agent. | 2012-08-23 |
20120213823 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES THEREOF AND USES THEREOF - There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability. | 2012-08-23 |
20120213824 | USE OF PUFAS FOR TREATING SKIN INFLAMMATION - The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I), | 2012-08-23 |
20120213825 | ANTIBIOTIC PRODUCT, USE AND FORMULATION THEREOF - An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the C | 2012-08-23 |
20120213826 | Use of Pro-Inflammatory Compounds for Promoting Bone Formation - The present invention provides methods, uses and compounds for promoting bone formation in a patient at a site in need thereof by the provision of a pro-inflammatory compound at the site. The site is generally a site of injury or a site of surgical intervention in the patient. Exemplary compounds include pro-inflammatory: cytokines. Inhibitors of indoleamine 2, 3, dioxygenase 1 are also provided in the methods and uses of the invention. | 2012-08-23 |
20120213827 | PROCESS FOR CONTROLLED CRYSTALLIZATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT FROM SUPERCOOLED LIQUID STATE BY HOT MELT EXTRUSION - A process for controlling the crystallization of certain hydrophobic active pharmaceutical ingredients (APIs) from a supercooled liquid state by hot-melt extrusion processing is described. Also described is a pharmaceutical composition comprising a solid crystalline dispersion of a cholesterol ester transfer protein inhibitor in a hydrophilic excipient matrix. In the process of the present invention, the API is fed to an extrusion system in a crystalline state contemporaneously with carrier excipients where it is first converted to a non-crystalline state by the application of heat and then subsequently recrystallized in-situ by the removal of heat and application of shear. Recrystallization of the API is controlled by carrier formulation design and the hot-melt extrusion process parameters; i.e. barrel temperature profile, feed rate, etc. | 2012-08-23 |
20120213828 | ADENOVIRUS VACCINE VECTOR AND METHODS OF USE - Ad40-based polynucleotides, viral vectors, methods of making such polynucleotides and viral vectors, pharmaceutical compositions that includes such polynucleotides and viral vectors, and uses of such compositions are disclosed herein. Generally, the Ad40-based polynucleotide includes an Ad40-based vector that includes a genetic modification that decreases expression of an E1 coding region and a heterologous polynucleotide. | 2012-08-23 |
20120213829 | DRY POWDER AEROSOLS OF NANOPARTICULATE DRUGS - There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof. | 2012-08-23 |
20120213830 | SUSPENSION COMPRISING BENZIMIDAZOLE CARBAMATE AND A POLYSORBATE - This invention is directed to a pharmaceutical composition for drinking water administration comprising benzimidazole carbamate particles having an effective average particle size of less than 450 mm and a Tween-type surfactant; a method for making the composition; use of the composition to make a medicament for controlling parasites; and use of said composition for the manufacture of a medicament or protecting animal from parasitic infection. | 2012-08-23 |
20120213831 | MICROSPHERES FOR ACTIVE EMBOLIZATION - The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) for use in embolization drug therapy. The present invention further relates to methods of embolization gene therapy, particularly for the treatment of angiogenic and non-angiogenic-dependent diseases, using the injectable compositions. | 2012-08-23 |
20120213832 | REMOVABLE DENTAL CURABLE COMPOSITION - A dental curable composition comprises (A) a polymerizable monomer and (B) an organic amine-based polymerization initiator, wherein (A′) a long-chain polymerizable monomer having a chain length of 17 or more atoms is contained in the component (A) and/or (C) a soft resin material are/is contained in the composition, and when the amount (parts by weight) based on 100 parts by weight of the component (A) of the component (A′) is represented by [a′] and the amounts (parts by weight) based on 100 parts by weight of the total of the components (A) and (B) of the components (A), (B) and (C) are represented by (a), (b) and (c), respectively, 70≦(a)≦99.99, 0.01≦(b)≦5 30, 1≦[a′]/5+(c)/1, 0≦[a′]≦95, and 0≦(c)≦250. | 2012-08-23 |
20120213833 | PREVOTELLA HISTICOLA PREPARATIONS AND THE TREATMENT OF AUTOIMMUNE CONDITIONS - This document provides methods and materials related to | 2012-08-23 |
20120213834 | ISOLATED PON1 POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME AND USES THEREOF IN TREATING OR PREVENTING ORGANOPHOSPHATE EXPOSURE ASSOCIATED DAMAGE - An isolated polypeptide comprising the amino acid sequence of serum paraoxonase (PON1) having catalytic efficiency of k | 2012-08-23 |
20120213835 | Compositions Comprising Peroxy alpha-Ketocarboxylic Acid and Methods For Producing and Using the Same - The present invention provides compositions comprising peroxy α-ketocarboxylic acid and methods for using the same. In some particular embodiments, compositions of the invention also include α-ketoesters. | 2012-08-23 |
20120213836 | DURABLE PEST REPELLENT AND PEST REPELLENT RESIN COMPOSITION - Disclosed is a pest repellent that has excellent heat resistance and solvent resistance, that can be kneaded into a resin molded article or a synthetic fiber, and that has excellent durability and persistence for which a pest repellent effect is sustained for a long period even when it is used for a long period or washed. | 2012-08-23 |
20120213837 | COMPOSITIONS AND METHODS FOR BIOACTIVE COATINGS TO IMPROVE ALLOGRAFT INCORPORATION - The invention provides compositions and methods useful for treating wounds and enhancing wound healing. The present invention discloses a continuous polymer coating system to provide sustained localized delivery of bioactive agents. The data demonstrate the efficacy of a bioactive coating comprising the polymer PLAGA and the agent FTY720, a selective agonist for sphingosine 1-phosphate receptors, and biologically active derivatives and analogs thereof, for use in wound healing. In vitro drug release studies validated 64% loading efficiency with complete release of compound following 14 days. Mechanical evaluation of healing bone showed significant enhancement of mechanical stability in FTY720 treatment groups. Superior osseous integration across the host-graft interface, significant enhancement in smooth muscle cell investment, and reduction in leukocyte recruitment were evident in FTY720 treated groups. The present invention is useful for enhancing angiogenesis for wound healing. | 2012-08-23 |
20120213838 | MEDICAL DEVICE FOR PLACEMENT INTO A LUMEN AND MANUFACTURING METHOD THEREOF - The present invention provides a medical device for placement into a lumen such as a stent and a catheter whose surface is uniformly and sufficiently coated with a drug, and a process thereof with easy way and with low cost. The medical device is coated with mixed particles of drug particles whose surface is modified with positive-charge and biocompatible nanoparticles. In the invention, a drug can be taken into a cell through the dissolution of the drug particle together with the biocompatible nanoparticle after a DES is placed in a biological body. | 2012-08-23 |
20120213839 | HYDROPHOBIC CROSS-LINKED GELS FOR BIOABSORBABLE DRUG CARRIER COATINGS - Coatings for medical devices, methods of making the coatings, and methods of using them are described. | 2012-08-23 |
20120213840 | OCULAR STRIPS - Ocular inserts including a cylindrical body, a lumen and a hydrophilic polymer and strips thereof are suitable for contact with an eye of a subject suffering from an eye disorder. While in contact with an eye, the ocular inserts may be used for releasing various agents, including pharmaceutically active agents, and effecting a treatment of one or more eye disorders. | 2012-08-23 |
20120213841 | OPHTHALMIC DRUG DELIVERY SYSTEM AND METHOD - A method to provide a therapeutic agent to an eye of a patient by implanting or inject a device that stably fits a particular location or position in the eye. The method thus provides agent inside the eye for a longer duration of agent release over a space-occupying area inside the eye. | 2012-08-23 |
20120213842 | METHODS OF MAKING AND USING COMPOSITIONS COMPRISING FLAVONOIDS - The subject invention relates to novel micoparticulate and soluble forms of flavonoids, and their synthesis. The invention also includes novel formulations of such flavonoids. Further, the invention includes novel methods of manufacturing the flavonoid formulations. The invention also relates to a wide variety of applications of the flavonoid formulations. | 2012-08-23 |
20120213843 | COMPOSITION FOR PROMOTING WOUND HEALING - A lipid layer forming wound healing promoting composition comprising volatile silicone oil, polar lipid, C | 2012-08-23 |
20120213844 | LIPOSOME COMPOSITION FOR TARGETING EGFR RECEPTOR - Short oligopeptides are provide which are capable of binding to the epidermal growth factor receptor on the surface of human tumor cells. Methods for using the peptides as targeting moieties in more complex compositions, such as conjugates of cytoxins, and/or structures, such as liposomal structures, for the purposes of drug delivery are also provided. | 2012-08-23 |
20120213845 | SKIN COMPOSITION COMPRISING AN EXFOLIATE, A BRIGHTENER AND A COLLAGEN BOOSTER, AND METHOD OF USING THE SAME - There is disclosed a composition that provides improved anti-aging benefits and creates a healthier skin using the combination of skin exfoliation, brightening, and collagen synthesis. In one embodiment, the composition comprises, a skin exfoliation ingredient such as citric acid and gluconolactone, at least one skin brightening ingredient, such licorice extract, and at least one collagen enhancing ingredient, such as hydroxyproline, bioactive polypeptides or combinations thereof. Depending on the end-use, various optional ingredients, such as moisturizers, anti-inflammatory agents, UVA/UVB protectants, and cleansers, may be added to the composition, which may take various forms, such as a cream, mousse, serum, or gel. | 2012-08-23 |
20120213846 | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration - Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug. | 2012-08-23 |
20120213847 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 2012-08-23 |
20120213848 | Treatment of Infection Using Single Chain Antibody Gene Therapy - A method for treating HIV and other intra-cellular parasites and toxins using intrabodies delivered to leukocytes. | 2012-08-23 |
20120213849 | CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available. | 2012-08-23 |
20120213850 | Controlled Release and Taste Masking Oral Pharmaceutical Composition - Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract. | 2012-08-23 |
20120213851 | SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING AN INTEGRASE INHIBITOR - Compressed tablets for oral administration containing raltegravir in the form of a pharmaceutically acceptable salt are described. The tablets comprise: (A) an intragranular component comprising (i) an effective amount of an alkali metal salt of raltegravir, (ii) optionally a first superdisintegrant, and (iii) a binder; and (B) an extragranular component comprising (i) a second superdisintegrant, (ii) a filler, and (iii) a lubricant. Methods for preparing the tablets and the use of the tablets, optionally in combination with other anti-HIV agents, for the inhibition of HIV integrase, for the treatment or prophylaxis of HIV infection, or for the treatment, delay in the onset, or prophylaxis of AIDS are also described. | 2012-08-23 |
20120213852 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The specification discloses compositions and methods for treating a soft tissue defect of an individual. | 2012-08-23 |
20120213853 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The specification discloses compositions and methods for treating a soft tissue defect of an individual. | 2012-08-23 |
20120213854 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS - Described herein are methods for treating a subject with combinations of polymer-agent particles and cyclodextrin polymer agent conjugates. The methods herein may be used to treat subjects identified with cancer, cardiovascular disorders, autoimmune disorders, or inflammatory disorders. Also described herein are compositions, dosage forms, and kits comprising polymer-agent particles and cyclodextrin polymer agent conjugates. | 2012-08-23 |
20120213855 | DOSAGE FORMS FOR WEAKLY IONIZABLE COMPOUNDS - This disclosure relates to dosage forms (e.g., solid dosage forms) comprising a drug-containing emulsion, a drug-containing microemulsion, a self-emulsifying oil composition, or a self-microemulsifying oil composition, wherein each comprises a weakly ionizable drug and a pH modifier. Also provided are pharmaceutical dosage forms (e.g., solid dosage forms) and methods of preparing the same. | 2012-08-23 |
20120213856 | Manufacturing Method of Microcapsule - A manufacture method of microcapsule, comprises a step of extraction, by extracting active substance from a sample of Chinese | 2012-08-23 |
20120213857 | Method for Producing Pancreatin Pellets - In order to avoid compromising the pharmacological effect of pancreatin caused by the addition of auxiliary materials or binding agents, a pancreatin pellet having a 100% pancreatin content consists exclusively of pancreatin with a residual moisture content of less than 3% by weight, preferably less than 1% by weight or less than 0.5% by weight. | 2012-08-23 |
20120213858 | ANTI-REFLUX INFANT NUTRITION - An infant formula for preventing gastro-esophageal reflux is disclosed comprising whey protein and/or casein, a galactomannan thickener, and a fermented milk-derived product. | 2012-08-23 |
20120213859 | PROCESS FOR DEMINERALIZATION OF BONE MATRIX WITH PRESERVATION OF NATURAL GROWTH FACTORS - A demineralized bone matrix is produced by a process in which a bone body is placed in a first processing solution comprising an acid to demineralize the bone body. The bone body is periodically removed from the first solution at specific time intervals to perform at least one test, such as a compression test, on a mechanical property of the bone body. When the test yields a desired result, the bone body is exposed to a second processing solution that is less acidic than the first, thus minimizing the exposure of the bone body to the harsh acidic conditions of the demineralization phase of the process. | 2012-08-23 |
20120213860 | XENON-BASED INHALABLE DRUG FOR TREATING OR PREVENTING INDUCED DYSKINESIA - The invention relates to the use of a gaseous drug based on gaseous xenon for inhalation for treating or preventing in mammals dyskinesia induced by a dopaminergic agonist. The invention is particularly useful for treating levodopa induced dyskinesia in patients being treated for Parkinson's disease. | 2012-08-23 |
20120213861 | 2-CHLOROPENTAFLUOROPROPENE COMPOSITIONS AND METHOD OF USE FOR EXTERMINATION OF RODENTIA - Rodenticide compositions that include 2-chloropentafluoropropene, and methods of using such rodenticide compositions, are provided. The rodenticide compositions can be used as fumigants in space fumigation applications. In some examples, the rodenticide compositions can be used as drop-in replacements for methyl bromide in existing rodenticide compositions and methods of exterminating rodents using methyl bromide. | 2012-08-23 |
20120213862 | Negative Ion-Releasing Silica Compositions and Methods of Preparing and Using the Same - Negative ion-releasing silica compositions and methods for their preparation and use are described herein. The compositions include silicon dioxide and gadolinium. Further described herein are products including the compositions. | 2012-08-23 |
20120213863 | THERAPEUTIC GAS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS - The use of gaseous oxygen for the production of a therapeutic gas for inhalation by a patient who has been identified as a person with a mitochondrial disorder or a coenzyme Q10 deficiency, for the treatment of mitochondrial disorders or Q10 deficiencies is disclosed. | 2012-08-23 |
20120213864 | METHOD OF MAKING A COMPOSITION AND THE USES THEREOF IN REMOVING OR DISSOLVING A CONTAMINANT FROM AN ENVIRONMENT - A composition which is effective in removing a wide variety of contaminants, such as organic compounds, from a wide variety of environments, such as printing systems, is provided. A process of preparing such composition includes contacting hydrogen peroxide, glycolic acid, and water. The process can additionally include contacting with one or more additional components such as isopropyl alcohol. | 2012-08-23 |
20120213865 | CLEANING AND SANITIZING FILM - A liquid mixture that forms a film on a surface which inhibits the life functions of bacteria. In particular the film may include copper or silver, or a combination thereof, to provide an environment hostile to bacteria and other infectious organisms. | 2012-08-23 |
20120213866 | METHOD AND SYSTEM FOR MODULATING SUBSTANCES AFFECTING BODILY PROCESSES - A method for establishing a treatment for promoting the formation of substances in an individual. The measured or assessed level of substances in the body are compared in order to determine the treatment to provide to an individual. | 2012-08-23 |
20120213867 | RAF INHIBITORS FOR THE TREATMENT OF THYROID CANCER - The invention relates to the use of an Raf inhibitor for the manufacture of pharmaceutical compositions for the treatment of thyroid cancer, more specifically papillary thyroid cancer (PTC); the use of a Raf inhibitor in the treatment of thyroid cancer, more specifically PTC; a method of treating warm-blooded animals including mammals, especially humans, suffering from thyroid cancer, more specifically PTC, by administering to a said animal in need of such treatment a dose effective against said disease of an Raf inhibitor. The invention also relates to the use of a Raf inhibitor in combination with a platin compound for the treatment of thyroid cancer, more specifically papillary thyroid cancer. | 2012-08-23 |
20120213868 | OIL-EXTRACTED PRODUCT OF INDIGO NATURALIS, AND PREPARATION PROCESS AND USES THEREOF - Disclosed herein are an oil-extracted product of indigo naturalis, and the preparation process thereof. Also disclosed are a pharmaceutical composition containing the oil-extracted product of indigo naturalis and a method for treating a human subject having or suspected to have a psoriatic disease such as skin psoriasis and nail psoriasis. | 2012-08-23 |
20120213869 | Pain Relieving Composition - A pain relieving composition that includes an anesthetic in the range of 0.5%-7.0% by weight (“w/w”), an anti-inflammatory agent in the range of 1.0%-11.0% w/w, a moisturizing agent in the range of 0.5%-12.0% w/w, a humescent in the range of 0.5%-13.0% w/w, a penetration enhancing agent in the range of 0.5%-7.0%, and a carrier solvent in the range of 40.0%-97.0% w/w to be used before and/or after procedures which cause damage to human skin. | 2012-08-23 |
20120213870 | COMPOSITION AND METHOD FOR TREATING LIVER DISEASE - A botanical composition for treating a patient with liver disease, e.g., Hepatitis C virus, is provided which includes dried fruit of | 2012-08-23 |
20120213871 | HERBAL SOLID FORMULATION AND PROCESS FOR PREPARING THE SAME - Disclosed is a herbal solid formulation comprising | 2012-08-23 |
20120213872 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES THEREOF AND USES THEREOF - There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability. | 2012-08-23 |
20120213873 | Miracle cream - This composition stimulates collagen production; specifically the composition is able to promote collagen production in human dermis. | 2012-08-23 |
20120213874 | HERBAL SOLID FORMULATION AND PROCESS FOR PREPARING THE SAME - Disclosed is a herbal solid formulation comprising | 2012-08-23 |
20120213875 | COSMETIC COMPOSITION FOR SKIN WHITENING COMPRISING THE EXTRACT OF MAGNOLIA SIEBOLDII AS ACTIVE INGREDIENT - Disclosed herein is a skin-whitening cosmetic composition containing an extract of | 2012-08-23 |
20120213876 | DEVICE FOR PRODUCING GRANULES MADE OF POLYMERIC MATERIALS - A device for producing granules has a water-cooled granulating mechanism for producing plastics material granules. A discharge line arranged downstream of the granulating mechanism discharges a starting mixture flow and a granule heat exchanger arranged downstream of the discharge line controls the temperature of the mixture containing the plastics material granules and cooling water using parallel fluid passages. The granule heat exchanger has an inlet and an outlet for a transmission heat exchanger medium. A drying mechanism arranged downstream of the granule heat exchanger dries the plastics material granules. The device also may have an energy recovery mechanism arranged downstream of the discharge line for recovering energy from a recovery cooling water flow, containing at least a part of the cooling water of the starting mixture flow. The device uses waste heat, transmitted to the cooling water to increase the performance of the device and improve the energy efficiency thereof. | 2012-08-23 |
20120213877 | INJECTION MOLD - An injection mold for molding an electronic product which has a terminal includes a movable mold, a first sliding block levelly defining a through-hole, a second sliding block, a supporting pole and a stationary mold. A top of the movable mold defines an opening of which a bottom defines a fastening hole for fastening a bottom of the terminal therein. An inner sidewall of the second sliding block defines a groove for restraining a top of the terminal. The first and second sliding blocks are located at two opposite sides of the opening to together define a cavity for molding the electronic product. The supporting pole is movably inserted in the through-hole and stretches into the cavity to resist against the top of the terminal. The stationary mold is positioned on the first and second sliding blocks, and defines a sprue channel connected with the cavity. | 2012-08-23 |
20120213878 | METHOD FOR VOLUME DIVISION OF DOUGH AND IMPLEMENTING DEVICE - The invention concerns a method for volume division of bread-making, bakery, and pastry dough and the like, contained in a hopper. The method includes allowing the dough to flow by gravity into a chamber capable of measuring an amount of dough to be divided and extending beneath an opening located at the base of the hopper. The chamber is at least partly closed. The volume division of the dough into dough pieces of the amount of dough contained in the chamber is started. The divided dough pieces from the chamber are removed to be set on a discharge carrier. The invention also concerns a device for implementing the method. | 2012-08-23 |
20120213879 | EMBOSSING SYSTEM AND PRODUCT MADE THEREBY WITH BOTH PERFORATE BOSSES IN THE CROSS MACHINE DIRECTION AND A MACRO PATTERN - An embossing system is provided for embossing at least a portion of a web comprising a first roll and at least a second roll. The first roll and second roll may define a first nip for embossing the web. At least one of the first roll and the second roll has elongated embossing elements extending substantially in the machine direction and optionally at least one of the first and second rolls has elongated embossing elements extending substantially in the cross-machine direction. At least one of the first roll and the second roll may also have perforate embossing elements extending substantially in the cross-machine direction that may or may not be elongated. The embossing elements are capable of imparting one or both of a cube embossing pattern or a perforate emboss on the web. In addition, the web may be creped with an undulatory creping blade. | 2012-08-23 |
20120213880 | MOLD FOR FORMING SKIN-INTEGRATED FOAM ARTICLE - A mold for forming a skin-integrated foam article, by setting a planar skin material in a cavity, and foam-molding a foam body in the cavity, so that the foam body adheres integrally to the skin material, is disclosed. The mold has a core mold that is pressed against a surface of a part of the skin material set in the cavity when the core mold is placed in a closed position, and forms a hollow portion that is open to the surface of the part of the skin material, in the foam body. The core mold has a protrusion formed on a pressing face thereof which is pressed against the surface of the part of the skin material, and the protrusion is pressed against the surface of the part of the skin material. | 2012-08-23 |
20120213881 | MOLDING DEVICE FOR FORMING COMPACT LENS BARREL - A molding device for forming a compact lens barrel includes a first mold part and a second mold part. The first mold part includes a generally cylindrical molding recess with an opening defined at an end thereof. The first mold part has a bottom surface facing toward the opening. A first protrusion is formed on the bottom surface. The first protrusion has a round, first top surface. The second mold part includes a core insert and a second protrusion formed on the core insert. The second protrusion has a round, second top surface. The second mold part is received in the molding recess with the second top surface contacting the first top surface. An annular surface portion of one of the first top surface and the second top surface is exposed. The annular surface portion has a width equal to or less than 0.005 mm. | 2012-08-23 |
20120213882 | SOLAR CELL MODULE MANUFACTURING DEVICE - There is provided a solar cell module manufacturing device that includes a molding tool used to mold a solar cell module and a heating unit heating the molding tool. The solar cell module manufacturing device includes heat supply suppressing means that is provided on the molding tool and suppresses the supply of heat to the sealing member when the molding tool in which a sealing member and solar cells have been received is heated by the heating unit. | 2012-08-23 |
20120213883 | INJECTION MOLD - An injection mold is adapted for ejecting out an insert-molding product and an injecting waste material connected with the insert-molding product one after another in turn. The injecting mold includes a fixed mold and a movable mold movably engaged with the fixed mold to define a chamber for molding the insert-molding product and a sprue channel for molding the injecting waste material therebetween. In the process of ejecting the insert-molding product and the injecting waste material out of the injection mold, The injection mold has at least one product ejector pin used to make the insert-molding product separated from the injecting waste material and then eject the insert-molding product out of the injection mold firstly, and at least one delay ejector pin used to eject the injecting waste material out of the injection mold after the insert-molding product are ejected out of the injection mold. | 2012-08-23 |